Aberdeen Group
PHAT icon

Aberdeen Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Aberdeen Group’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-16,776
Closed -$552K – 960
2020
Q2 		$552K Buy
+16,776
New +$645K ﹤0.01% 857

Other funds holding PHAT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Aberdeen Group's PHAT Position: Q3 2020 in Review

Aberdeen Group sold out of Phathom Pharmaceuticals (PHAT) in Q3 2020, closing a stake of 16,776 shares — an estimated $552K sold.

Aberdeen Group first reported a position in PHAT in Q2 2020 and held it in 1 quarter. The position peaked at $552K in Q2 2020. 58 funds tracked by Wall St. Rank hold PHAT as of Q3 2020.

  • Aberdeen Group reported no remaining Phathom Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Aberdeen Group sold 16,776 Phathom Pharmaceuticals shares in Q3 2020, an estimated $552K.
  • Aberdeen Group first reported a position in Phathom Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Aberdeen Group's Phathom Pharmaceuticals position peaked at $552K in Q2 2020.
  • 58 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2020.

Based on Aberdeen Group's 13F filing for Q3 2020, filed 21 Oct 2020.